Hemodynamic effects of eight-day octreotide and propranolol administration in portal hypertensive rats.
Octreotide and propranolol are both effective portal hypotensive drugs in the control or prevention of variceal bleeding. The present study was undertaken to investigate the hemodynamic effects of octreotide and propranolol, alone or in combination, in portal hypertensive rats. Portal hypertension was induced by partial portal vein ligation. Portal hypertensive rats were allocated into one of the four groups: vehicle group (saline, 0.5 ml/day), octreotide group (100 microg/kg/12 hr), propranolol group (30 mg/kg/day), and octreotide (100 microg/kg/12 hr) plus propranolol (30 mg/kg/day) group. Propranolol or saline was administered by gavage, octreotide by subcutaneous injection. Drug was given one day before ligation and continued for eight consecutive days. Systemic as well as splanchnic hemodynamic parameters were measured thereafter. The portal venous pressure, portal tributary blood flow, and cardiac index were significantly reduced by octreotide, propranolol, or octreotide plus propranolol in portal hypertensive rats. Portal territory, systemic, and renal vascular resistances were significantly enhanced, while hepatic arterial blood flow significantly reduced, in the octreotide and octreotide plus propranolol groups as compared to vehicle group. Our results showed that eight-day administration of octreotide, propranolol, or octreotide plus propranolol led to portal hypotensive and antihyperdynamic effects in portal hypertensive rats. Overall, octreotide treatment alone resulted in better antihyperdynamic profiles than propranolol treatment alone. The combination of octreotide and propranolol offered no therapeutic benefits and was slightly less effective than octreotide alone.
Huang
Y T
YT
Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Veterans General Hospital, Taipei, Taiwan.
Cheng
Y R
YR
Lin
H C
HC
Hou
M C
MC
Lee
S D
SD
Hong
C Y
CY
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D004359:Drug Therapy, Combination; D006439:Hemodynamics / Q000187:drug effects; D006728:Hormones / Q000494:pharmacology* / Q000627:therapeutic use; D006975:Hypertension, Portal / Q000188:drug therapy* / Q000503:physiopathology*; D008297:Male; D015282:Octreotide / Q000494:pharmacology* / Q000627:therapeutic use; D011168:Portal System / Q000187:drug effects*; D011433:Propranolol / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D014655:Vascular Resistance / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D006728:Hormones; D011433:Propranolol; D015282:Octreotide